ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 2, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 2, 2010
News
Week of Nov. 29, 2010: Company and People Notes: Lonza Forms Agreements with Two Partners; Covance Makes Executive Appointments; and More.
Lonza Forms Agreements with Two Partners; Covance Makes Executive Appointments; and More.
Genzyme Meets Consent Decree Deadline
By Erik Greb
Genzyme (Cambridge, MA) officially ended fill?finish operations at its Allston Landing, Massachusetts, plant for products sold in the United States, thereby fulfilling a requirement of a US Food and Drug Administration consent decree.
GSK Plans UK-Based R&D and Manufacturing Investment
By Patricia Van Arnum
GlaxoSmithKline (GKS, London) outlined a plan to invest EUR 500 million ($649 million) in research and development (R&D) and related manufacturing in the United Kingdom conditioned on the successful implementation of a so-called "patent box" measure by the UK government.
Survey Offers Mixed Results of FDA's Performance
By Patricia Van Arnum
PricewaterhouseCoopers (PwC) released the results of a survey that analyzed the relationship of life-science companies with the US Food and Drug Administration and their views of the agency.
Regulatory Roundup: EMA Publishes New Transparency Policy, Releases Guideline for Biosimilar mAbs.
EMA Publishes New Transparency Policy, Releases Guideline for Biosimilar mAbs.
FDA Issues New Guidance for Industry on ANDAs: Impurities in Drug Products
By Angie Drakulich
The US Food and Drug Administration issued late last week a new guidance for industry on impurities in drug products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here